Who is sponsoring NCT03662646?

NCT03662646 is sponsored by Tel-Aviv Sourasky Medical Center.

What drugs are being tested in NCT03662646?

Interventions in NCT03662646: no intervention performed- observational only.

What condition does NCT03662646 study?

NCT03662646 studies Inflammatory Bowel Diseases, Circadian Dysregulation.

Is NCT03662646 still recruiting?

NCT03662646 is currently completed. Last updated 22 February 2023.

Last reviewed 2023-02-22 · How we verify

NCT03662646

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Circadian Rhythms in Patients With IBD or Celiac Disease Upon Diagnosis and Medical Follow-up

Completed Last updated 22 February 2023

What this trial tests

trial testing no intervention performed- observational only in Inflammatory Bowel Diseases in 80 participants. Completed in 31 December 2022.

Timeline

31 August 2017

Primary endpoint
31 July 2022

31 December 2022

Quick facts

Lead sponsor	Tel-Aviv Sourasky Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	80
Start date	31 August 2017
Primary completion	31 July 2022
Estimated completion	31 December 2022
Sites	1 location across Israel

Drugs / interventions tested

no intervention performed- observational only

Conditions studied

Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →
Circadian Dysregulation — all drugs for Circadian Dysregulation →

Sponsor

Tel-Aviv Sourasky Medical Center

Who can join

Adults 6 to 25, any sex, with Inflammatory Bowel Diseases or Circadian Dysregulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

patients 6-25 years old upon diagnostic evaluation will be recruited . study population will comprise of two groups: newly diagnosed IBD patients/ Celiac disease and healthy controls. upon enrollment, subjects will fill out sleeping habits questioners, demographic data, medical history. blood samples will be drawn for CRP and clock gene expression in systemic WBC. intestinal biopsies will be snap frozen for clock gene extraction and amplification only for patients with IBD.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Clock Gene Disruption Is an Initial Manifestation of Inflammatory Bowel Diseases.
Weintraub Y, Cohen S, Chapnik N, Ben-Tov A, et al · · 2020 · cited 55× · PMID 30981000 · DOI 10.1016/j.cgh.2019.04.013
Inverse Relationship Between Clock Gene Expression and Inflammatory Markers in Ulcerative Colitis Patients Undergoing Remission.
Weintraub Y, Cohen S, Anafy A, Chapnik N, et al · · 2023 · cited 6× · PMID 36745299 · DOI 10.1007/s10620-023-07847-y
Circadian clock gene disruption in white blood cells of patients with celiac disease.
Weintraub Y, Cohen S, Yerushalmy-Feler A, Chapnik N, et al · · 2024 · cited 4× · PMID 37524198 · DOI 10.1016/j.biochi.2023.07.020
Intestinal inflammation induces glymphatic remodeling, priming early neurodegenerative signals in male mice.
Ciampi C, Fagiani F, Murtaj V, Comella F, et al · · 2025 · cited 1× · PMID 41065132 · DOI 10.1002/alz.70640

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

NCT07520747 — A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea · recruiting
NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07033208 — Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance · NA · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06453317 — Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 2 · recruiting

Other Tel-Aviv Sourasky Medical Center trials

Trials by the same sponsor.

NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03662646 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
Last refreshed: 22 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03662646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing